Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
1561-1580 of 2,120 trials

Staphylococcus Aureus Bacteremia: Shorter Antibiotic Treatment

We are studying whether 4 weeks of antibiotic treatment is as effective as 6 weeks for patients with complicated Staphylococcus aureus bacteremia who have improved after initial therapy.

Staphylococcus aureus Bacteremia6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteInfectious Diseases

Heart Failure: Hyperpolarized MRI Study

We are investigating how the heart uses a substance called pyruvate in patients with heart failure. This study aims to see if a new imaging method can improve our understanding of heart metabolism.

Heart Failure>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementCardiologyInternal Medicine

Ovarian Cancer: Tinzaparin and Biomarkers

We are studying how tinzaparin affects cancer marker levels in patients with advanced ovarian cancer receiving chemotherapy. This trial also looks at the drug's safety and its impact on immune and blood factors.

Epithelial Ovarian Cancer6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Primary Immune Thrombocytopenia: Efgartigimod IV Study

We are testing the safety and effectiveness of efgartigimod IV in adults with primary immune thrombocytopenia. This study will help us understand if it can improve platelet counts and reduce bleeding risks.

Idiopathic Thrombocytopenic Purpura (ITP)>2 yearsConfirmation phase (III)>20 visitsInvestigational MedicinesCost ReimbursementHematologyInternal Medicine

Advanced Solid Tumors: ALE.P02 Treatment Study

We are investigating a new antibody-drug conjugate, ALE.P02, for adults with certain advanced solid tumors. The study aims to evaluate its safety and how well it may work against these tumors.

Advanced or Metastatic Squamous Solid Tumors1-2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboCost ReimbursementOncology

Aggressive Multiple Sclerosis: Stem Cell Transplant Study

We are investigating whether stem cell transplantation can prevent disease activity in people with aggressive multiple sclerosis. The study will also monitor safety and other health changes over time.

Relapsing-Remitting Multiple Sclerosis>2 yearsEfficacy phase (II)16-20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesHematologyNeurology

Myocarditis: Anakinra Treatment Study

We are investigating whether adding Anakinra to standard treatments helps patients with virus-negative myocarditis. This study aims to evaluate its safety and effectiveness compared to usual care.

Virus-Negative Myocarditis6-12 monthsEfficacy phase (II)≤5 visitsStandard MedicinesCardiologyInternal Medicine

Kidney Transplant: Alkaline Phosphatase Treatment

We are studying whether alkaline phosphatase can help prevent kidney injury after transplantation in deceased donor recipients. This may reduce the need for dialysis and improve kidney function recovery.

End-Stage Kidney DiseaseEfficacy phase (II)Investigational MedicinesInternal MedicineNephrology

Decompensated Cirrhosis: New Human Albumin Solution

We are studying a new human albumin solution to see if it is safer and more effective than the standard treatment for patients with decompensated cirrhosis. This research aims to improve clinical outcomes for those needing long-term albumin therapy.

Decompensated Cirrhosis1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHepatologyInternal Medicine

OCTAPLEX for Major Bleeding in Patients on Blood Thinners

We are studying whether a higher dose of OCTAPLEX can effectively stop major bleeding in patients taking direct oral anticoagulants. The trial also looks at the safety of this treatment during emergencies.

Coagulation DisorderAcute Major Bleeding with DOAC Therapy≤3 monthsConfirmation phase (III)No PlaceboStandard MedicinesHematology

Atopic Dermatitis: RO7790121 Treatment Study

We are testing a new medication, RO7790121, for people with moderate to severe atopic dermatitis. The study aims to see if it can significantly improve skin symptoms compared to a placebo.

Atopic DermatitisEfficacy phase (II)≤5 visitsInvestigational MedicinesPartially RemoteAllergologyDermatology

Metastatic Urothelial Carcinoma: Livmoniplimab and Budigalimab Study

We are studying a new combination of livmoniplimab and budigalimab for adults with metastatic urothelial carcinoma who have not responded to prior treatments. The goal is to see if this combination improves survival compared to standard chemotherapy.

Urothelial CarcinomaMetastatic Urothelial CarcinomaEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Advanced Neuroendocrine Carcinomas: Enfortumab-Vedotin Study

We are studying a new treatment for patients with advanced Neuroendocrine Carcinomas who cannot use standard chemotherapy. The goal is to see if this treatment can help shrink tumors and improve survival.

Neuroendocrine Carcinoma>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesEndocrinologyOncology

Diffuse Large B-Cell Lymphoma: Zilovertamab Vedotin with R-CHP

We are studying a new treatment combining zilovertamab vedotin with standard therapy for people with diffuse large B-cell lymphoma. The goal is to see if this combination works better than another treatment option.

Diffuse Large B-Cell Lymphoma>2 yearsEfficacy phase (II)Investigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Emicizumab Dosing in Congenital Hemophilia A Patients

We are studying whether personalized dosing of emicizumab can effectively prevent bleeding in patients with congenital hemophilia A compared to standard dosing. This trial also examines the impact on quality of life and treatment costs.

Hemophilia A1-2 yearsConfirmation phase (III)Monitoring phase (IV)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementHematology

Head and Neck Cancer: INBRX-106 with Pembrolizumab

We are studying whether adding INBRX-106 to pembrolizumab helps patients with recurrent or metastatic head and neck cancer. This trial focuses on effectiveness, safety, and quality of life for those with high PD-L1 expression.

Head and Neck Squamous Cell CarcinomaEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementOncology

Neuroblastoma: 177Lu-DOTATATE Therapy for Children

We are evaluating a new radioactive treatment for children with refractory or recurrent neuroblastoma. The study aims to find the safest dose and assess how well the treatment works.

Recurrent or Refractory Neuroblastoma≤3 monthsSafety phase (I)No PlaceboInvestigational MedicinesOncologyPediatrics

Juvenile Idiopathic Arthritis: Biosimilar vs. Original Medications

We are studying whether switching between biosimilar and original anti-TNF medications helps children with Juvenile Idiopathic Arthritis maintain disease control. The trial will evaluate safety, effectiveness, and the occurrence of side effects.

Juvenile Idiopathic Arthritis>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesRheumatology

Ischemic Stroke: DOAC Intravenous Thrombolysis Trial

We are studying whether intravenous thrombolysis is more effective than standard care for patients with ischemic stroke who have recently taken direct oral anticoagulants. This research aims to improve recovery outcomes for these patients.

Acute Ischemic Stroke>2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteInternal MedicineNeurology

Kidney Transplant: Belatacept vs. Anticalcineurins

We are studying whether switching from anticalcineurins to Belatacept improves blood vessel function and reduces arterial stiffness in kidney transplant patients. This may help enhance overall cardiovascular health.

Kidney Transplant>2 yearsMonitoring phase (IV)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementNephrology